Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
"I think the problem with giving this medication to people who really don't have an indication for it is they assume all the risks of it, plus the risk of weight regain, which may be adverse for their health," she says
1 Participants were randomly assigned to receive Wegovy 2.4 mg or a placebo, alongside lifestyle counselling, for 68 weeks
In addition to significant weight loss, Wegovy is the only GLP-1 for adults with obesity that is proven to reduce the risk of events such as stroke, heart attack, or cardiovascular death in those who also have known heart disease, said Jamey Millar, the executive vice president of Novo Nordisks US operations
Brush the teeth and floss regularly
Wegovy Wegovy is the higher-dose (2.4 mg) semaglutide injection FDA-approved specifically for chronic weight management, and the first weight-loss medication also FDA-approved to lower the risk of major cardiovascular events in adults with known heart disease and obesity or overweight
